What is the correlation between FibroScan liver stiffness measurements, the AST/ALT ratio, the AST to platelet ratio index (APRI), and the Fibrosis‑4 (FIB‑4) index?

Correlation Between Non-Invasive Liver Fibrosis Tests

FibroScan (transient elastography) demonstrates the strongest correlation with actual liver fibrosis staging, followed by APRI and FIB-4, while AST/ALT ratio shows the weakest correlation among these markers. 1

Diagnostic Performance Hierarchy

For Significant Fibrosis (≥F2):

• FibroScan (>6.0-8.0 kPa): Sensitivity 75.1%, Specificity 79.3% 1
• APRI (>0.5): Sensitivity 72.3%, Specificity 63.7% 1
• FIB-4 (>1.45): Sensitivity 72.6%, Specificity 66.9% 1
• AST/ALT ratio: Limited diagnostic accuracy, primarily useful when >1.0 (PPV 73.7-100%) 2

For Advanced Fibrosis (≥F3):

• FibroScan (>8.0-11.0 kPa): Sensitivity 80.4%, Specificity 85.2% 1
• FIB-4 (>1.45): Sensitivity 72.6%, Specificity 66.9% 1
• APRI: Less reliable at this stage

For Cirrhosis (F4):

• FibroScan (>11.0-14.0 kPa): Sensitivity 82.6%, Specificity 89.0% 1
• APRI (>1.0): Sensitivity 57.1%, Specificity 73.5% 1
• FIB-4 (>3.25): Positive predictive value 65% 2

Correlation Strength Between Tests

Direct correlation studies reveal:

• FibroScan vs APRI: Moderate-to-strong correlation (r=0.667-0.682) 3, 4
• FibroScan vs FIB-4: Strong correlation (r=0.507-0.572) 3, 5, 4
• FibroScan vs AST/ALT: Weak correlation (r=0.251-0.419) 6, 4
• APRI vs FIB-4: Similar diagnostic performance, though FIB-4 slightly superior for cirrhosis 7

Clinical Application Algorithm

Step 1: Initial Screening

Use APRI or FIB-4 as first-line tests (low cost, widely available):

• APRI >0.5 or FIB-4 >1.45: Suggests significant fibrosis (≥F2) 1
• APRI >1.0 or FIB-4 >3.25: Suggests cirrhosis 1

Step 2: Confirmatory Testing

When blood markers suggest fibrosis, obtain FibroScan:

• >7.0 kPa: Confirms significant fibrosis 1
• >12.5 kPa: Confirms cirrhosis 1

Step 3: Dual Cutoff Strategy

For APRI in hepatitis B 1:

• Low cutoff (>0.5): Rules out significant fibrosis (high sensitivity)
• High cutoff (>1.5): Rules in significant fibrosis (high specificity)
• Indeterminate results (0.5-1.5): Require FibroScan or repeat testing

Critical Caveats

AST/ALT ratio limitations:

• Increases with age and may overestimate fibrosis in elderly patients 7
• Affected by acute inflammation, making it unreliable during hepatitis flares 2
• Normal value <0.8; >1.0 suggests advanced fibrosis but lacks precision 2

FIB-4 limitations:

• Incorporates age, leading to overestimation in patients >65 years 7
• Less accurate in patients with normal ALT 1

FibroScan limitations:

• Unreliable in obesity (may require XL probe) 2
• Falsely elevated with acute hepatitis, recent food intake, congestive heart failure, or extrahepatic cholestasis 2, 8
• Cannot distinguish inflammation from fibrosis 2

APRI advantages:

• Most cost-effective and accessible 1
• Best correlation with FibroScan among blood markers 3, 4
• Superior to AST/ALT ratio for all fibrosis stages 4

Disease-Specific Considerations

In chronic hepatitis C: FibroScan cutoffs 7.1-8.8 kPa for ≥F2, 12.5-14.6 kPa for cirrhosis (AUROC 0.95-0.97) 2

In NAFLD/MASLD: FIB-4 shows closer correlation to FibroScan than APRI, with optimal cutoff 1.65 for advanced fibrosis 5, 4

In chronic hepatitis B: WHO 2024 guidelines recommend APRI >0.5 or FibroScan >7.0 kPa to identify treatment candidates 1

Practical False Positive/Negative Rates

In a population with 25% prevalence of significant fibrosis 1:

• APRI (>0.5): 26.2% false positives, 6.8% false negatives
• FibroScan (>7.0 kPa): 15.8% false positives, 6.3% false negatives

The superior specificity of FibroScan reduces unnecessary treatment while maintaining similar sensitivity to blood markers 1, making it the preferred confirmatory test when available 8.